FibroGen, Inc. (NASDAQ:FGEN) – Analysts at SVB Leerink raised their Q3 2021 earnings per share (EPS) estimates for FibroGen in a research note issued to investors on Tuesday, May 11th. SVB Leerink analyst G. Porges now forecasts that the biopharmaceutical company will post earnings per share of $0.20 for the quarter, up from their prior estimate of $0.16. SVB Leerink currently has a “Outperform” rating and a $56.00 target price on the stock.
A number of other equities analysts also recently commented on the company. Mizuho restated a “neutral” rating and issued a $29.00 price objective on shares of FibroGen in a report on Tuesday, April 13th. JPMorgan Chase & Co. upgraded FibroGen from an “underweight” rating to a “neutral” rating in a report on Tuesday, April 13th. Bank of America upgraded FibroGen from a “neutral” rating to a “buy” rating and set a $47.00 price objective on the stock in a report on Wednesday, March 31st. Raymond James restated a “sell” rating on shares of FibroGen in a report on Wednesday, April 7th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $45.00 price objective (down previously from $75.00) on shares of FibroGen in a report on Monday, March 8th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $47.17.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Monday, May 10th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.12. The business had revenue of $38.40 million during the quarter, compared to analyst estimates of $59.48 million. FibroGen had a negative net margin of 191.78% and a negative return on equity of 48.19%. The firm’s revenue was up 57.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.89) earnings per share.
In other news, Director Thomas F. Kearns, Jr. sold 18,000 shares of the firm’s stock in a transaction on Thursday, March 11th. The shares were sold at an average price of $35.02, for a total value of $630,360.00. Following the sale, the director now owns 166,164 shares in the company, valued at $5,819,063.28. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Kalevi Kurkijarvi sold 6,000 shares of the firm’s stock in a transaction on Wednesday, February 17th. The stock was sold at an average price of $52.40, for a total transaction of $314,400.00. Following the completion of the sale, the director now owns 39,100 shares in the company, valued at approximately $2,048,840. The disclosure for this sale can be found here. Company insiders own 3.39% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Brown Advisory Inc. grew its stake in shares of FibroGen by 34.9% in the first quarter. Brown Advisory Inc. now owns 803,993 shares of the biopharmaceutical company’s stock worth $27,907,000 after acquiring an additional 207,791 shares during the last quarter. Ghost Tree Capital LLC acquired a new stake in shares of FibroGen in the first quarter worth $4,339,000. Lazard Asset Management LLC acquired a new stake in shares of FibroGen in the first quarter worth $60,000. Stifel Financial Corp grew its stake in shares of FibroGen by 10.1% in the first quarter. Stifel Financial Corp now owns 113,737 shares of the biopharmaceutical company’s stock worth $3,948,000 after acquiring an additional 10,454 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of FibroGen in the first quarter worth $411,000. Institutional investors and hedge funds own 75.05% of the company’s stock.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
See Also: Special Dividends
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.